YOUR DAILY PEPTIDE BRIEFING / SCIENCE / COMMUNITYNew source checks every six hours
Daily Peptide StackNEWS • RESEARCH • COMMUNITY
THE NEWS STACK / SOURCE NOTE

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH).

A source-backed record from the peptide news monitor, with the original source linked below.

BEFORE YOU READ

This page links to the original record; it is not an independent analysis or clinical recommendation.

← Back to Trials Stack
Trials StackClinicalTrials.gov

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Clinical trial record NCT07575399 was updated or published. See the registry for its current status, eligibility, and results (if reported).

Open original source ↗

Collected Nov 6, 2026. Third-party data may change. Consult the original publication or registry for complete methods, findings and status.